We have established a robust protocol for longitudinal fMRI in mice at high field MRI using a medetomidine anesthesia. Electrical forepaw stimulation in anesthetized animals is widely used to produce BOLD contrast in the primary somatosensory cortex. To preserve neuronal activity, most fMRI experiments used α-chloralose to produce sedation, but severe side effects make this procedure unsuitable for survival experiments. As advantageous alternative, the α 2 -adrenergic receptor agonist medetomidine has been applied successfully to permit longitudinal fMRI studies in rats. With the advent of transgenic technology, mouse models have become increasingly attractive raising the demand for implementation of a suitable fMRI protocol for mice. Therefore, we investigated the use of medetomidine for repetitive fMRI experiments in C57BL/6 mice. We evaluated the optimal medetomidine dose for subcutaneous application. Somatosensory evoked potentials (SSEPs) in the contralateral somatosensory cortex were recorded to assess brain activity under medetominidine following forepaw stimulation. Repetitive administration of medetomidine, the requirement for longitudinal brain activation studies, was well tolerated. Using the forepaw stimulation paradigm, we observed BOLD contrast in the contralateral somatosensory cortex in ∼ 50% of the performed scans using gradient echo-echo planar imaging (GE-EPI). However, imaging the small mouse brain at high field strength is challenging and we observed strong susceptibility artifacts in GE-EPI images in the cortex. We have developed an agar gel cap for successful compensation of these artifacts as prerequisite for successful mouse fMRI at 11.7T. The established protocol will be suitable for brain activation studies in transgenic animals and for studies of functional deficit and recovery after brain injury in mice.
Introduction
Functional magnetic resonance imaging (fMRI) using endogenous blood-oxygenation-level-dependent (BOLD) contrast (Ogawa et al., 1990 ) is a widely used technique to study brain activity non-invasively. Neuronal activation increases local energy demands and O 2 consumption, which leads to a shift in the relative concentration of oxygenated and deoxygenated haemoglobin in the capillary bed. This produces a susceptibility difference, which is the basis of BOLD imaging. The most common fMRI paradigm in rodents requires electrical stimulation of the fore-or hindlimbs to produce BOLD contrast in the corresponding regions of the primary somatosensory (S1) cortex (Bock et al., 1998) . For this purpose, most studies employ α-chloralose to produce sedation and preserve neuronal activity (Ueki et al., 1992) . However, these experiments are acute protocols (Silverman and Muir, 1993 ) and as such, alternative protocols have been established to perform longitudinal and non-invasive fMRI. Recently, the use of the α 2 -adrenergic receptor agonist medetomidine was introduced as an anesthetic for fMRI (Weber et al., 2006) and is now being used frequently in fMRI studies in the rat (Pawela et al., 2008; Weber et al., 2008; Zhao et al., 2008) .
Medetomidine produces sedation, analgesia and muscle relaxation by binding to central α 2 -adrenoreceptors located primarily in the brainstem (Ruffolo and Hieble, 1994) . It decreases the release of noradrenalin, thereby causing a general inhibition of the sympathetic nervous system (Sinclair, 2003) .
Up to now, it has been difficult to perform fMRI in mice. One reason for this is that it is extremely challenging to maintain tight control over physiological parameters in the mouse. Another reason is that the small neuroanatomical functional unit of the mouse requires high field strength to be resolved. Furthermore, the small mouse head leads to stronger susceptibility artifacts in GE-EPI with increasing field strength causing signal loss in the prominent brain structures of interest. To date, very few studies have attempted fMRI in the mouse. The first of which employed the classical α-chloralose paradigm and hindlimb stimulation combined with a gradient echo fast low angle shot (FLASH) sequence at 11.7 Tesla (T) (Ahrens and Dubowitz, 2001 ). They reported a 7% BOLD change in the somatosensory cortex, which was even higher in the draining veins. Subsequent studies employed low levels of isoflurane and intravenous contrast agent to measure changes in cerebral blood volume (CBV) at 7 T following hindpaw stimulation (Mueggler et al., 2001) , or BOLD change at 9.4 T with spin echo-echo planar imaging (SE-EPI) (Nair and Duong, 2004) . In these studies, electrical stimulation of the hindpaws ranged up to 6 mA, which is quite high but was required, most likely because isoflurane strongly suppresses neural activity. Therefore, the present study was designed to investigate the feasibility of establishing the medetomidine protocol, already proven very successful in rats, to produce sedation in mice for the purpose of fMRI. It was the goal to establish a robust protocol suitable for longitudinal brain activation studies in mice.
Materials and methods

Animals
Animal experiments were performed in accordance with the German Laws for Animal Protection and were approved by the local animal care committee and governmental body (Bezirksregierung Köln). Twenty-nine adult male C57BL/6 mice (20-35 g body weight) were used. Animals were housed individually at a 12/12 h light/dark cycle and had ad libitum access to water and standard diet.
Anesthesia
All animals were initially anesthetized with 4% isoflurane in O 2 :N 2 O (30:70). Isoflurane was reduced to 1.5% for maintenance during preparation. Isoflurane was required during preparation primarily to prevent the pain response to insertion of the infusion needle, insertion of the stimulation electrodes, and scalp incision for the SSEP procedure. Body temperature was continuously monitored with a rectal probe and maintained at 37.0 ± 0.5°C with in-house feedback controlled water or electrical blankets. Respiration rate was continuously monitored using a pressure sensitive pad and DASYLab software (National Instruments, Austin, TX, USA). When respiration was stable at 110-130 breaths per min, animals received a subcutaneous bolus of medetomidine (Domitor®, Pfizer, Karlsruhe, Germany) through a 23 Gauge (G) needle placed into the back that was connected to a 0.58 mm inner diameter polythene tubing, and administered via a syringe pump (Kent Scientific Corporation, Torrington, USA) outside the magnet room. Isoflurane was slowly discontinued over the course of the next 10 min (by approximately 0.2% every 1 min starting 3 min after bolus administration) so that no isoflurane was available at 10 min after bolus administration. When respiration rate decreased more than 50 bpm in the first 3 min after bolus administration, isoflurane was discontinued faster. At the time point of 10 min after bolus administration, a subcutaneous infusion of medetomidine was started and the N 2 O in the inhalation gas was replaced by N 2 . At the end of the experiment, mice received an intraperitoneal injection of atipamezole (Antisedan®, Pfitzer) at five times the initial dose of medetomidine in order to reverse the effects.
Experimental design
The first objective was the evaluation of the optimal dose of medetomidine for mice. Theoretically, the optimal dose would provide sufficient sedation for a maximum period of time and allow for full recovery after the experiment was concluded. The second objective was to establish whether neuronal activity was preserved following medetomidine sedation with the optimized dose. This was accomplished by recording somatosensory evoked potentials (SSEPs) during forepaw stimulation. The third objective was to optimize MR image quality using a combination of shimming techniques and homedeveloped agar gel head caps (cf. below). The fourth objective was to perform serial fMRI measurements in the same mice using an identical forepaw stimulation paradigm, thus proving the protocol suitability for longitudinal functional studies.
Dose response
Six different doses of medetomidine (bolus: 0.2, 0.3, 0.4, 0.5, 0.6, and 0.7 mg/kg; and corresponding infusion: 0.4, 0.6, 0.8, 1.0, 1.2, 1.4 mg/kg/ h respectively; n = 2 each) were tested in 12 mice. Sedation duration (i.e. time between bolus administration and the time when the animal woke up), respiration rate and recovery were monitored for each dose. Additionally, trend of partial pressure of carbon dioxide (pCO 2 ) was monitored with a transcutaneous blood gas analyzer (TCM4, Radiometer Copenhagen) optimized for rodent recordings. For this, a 2 cm circle of fur was removed from the abdomen with an electrical razor and depilatory cream, and an electrode was secured with a fixation ring and contact fluid. Once sedation became light and animals began to move, they received the corresponding dose of atipamezole (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 mg/kg) and were returned to their home cages.
SSEP recording
Somatosensory evoked potentials were recorded in mice (n =5) sedated with 0.3 mg/kg medetomidine, which was determined as the optimal dose from the dose response experiments. Animals were originally anesthetized with isoflurane and positioned in a stereotaxic apparatus. The skin over the skull was retracted and custom-built silverball electrodes were placed over the left and right S1 cortices (2.4 mm lateral from bregma) with conducting gel. Home-built steel needle (30 G) electrodes were placed subcutaneously into both forepaws. Once preparation was complete, medetomidine sedation was initiated. Stimulation was performed with 100 rectangular pulses (2 mA, 6 Hz, 0.3 ms; STG 1004 Stimulator, Multi Channel Systems, Reutlingen, Germany). Each paw was stimulated 4 times with random sequencing between the paws. The response was recorded and averaged with DasyLab software so that one evoked potential was obtained per stimulation period. At the conclusion of the experiments, low doses of isoflurane (0.8-1%) were administered in order to suture the wound, and local anesthetic (Xylocain Gel 2%, AstraZeneca, Wedel, Germany) was applied to minimize pain. Animals were subsequently recovered with 1.5 mg/kg of atipamezole and returned to their home cages.
MRI
MRI experiments were conducted at a horizontal 11.7T Biospec system (Bruker BioSpin, Ettlingen, Germany) with a 16 cm diameter bore magnet and using ParaVision 5 software. RF transmission was achieved with a quadrature resonator (Bruker) and the signal was detected using a mouse quadrature surface coil (Bruker). Animals were mounted in an animal holder (Bruker) using a toothbar and earbars for stable positioning. Body core temperature was controlled and monitored with an in-house designed automated temperature control unit complete with water blanket.
Image quality experiments
Single shot gradient echo-echo planar imaging (GE-EPI) was employed on two mice using the following imaging parameters: TE approximately equal to the T 2 * value of the cortex (17.5 ms), TR = 3000 ms, BW = 150 kHz, 1 mm slice thickness, field of view = 1.28 × 1.28 mm 2 , matrix 64 × 64 pixels. Microscopic field gradients at interfaces of air, bone and brain resulted in signal loss artifacts in the S1 cortex. Therefore, different shim methods were used to improve image quality: global shim, local shim and field map-based shimming (MAPSHIM, ParaVision 5). The field map, a 3D volume of the B0 field distribution, was acquired with TE = 2 ms, TR = 20 ms, and isotropic resolution of (150 µm) 3 . The shim volume for all shim methods was a (4 mm) 3 cube positioned in the mouse brain including the S1 cortex. As no improvement of image quality was visible, field maps were acquired after each shim method in order to visualize the field line distributions. Additionally, field maps were acquired for different positions of the S1 relative to the isocenter (−4, −2, 0, 2, and 4 mm along the z-axis) to locate the origin of distortions. Finally, in order to reduce field inhomogeneity, a 2% agarose gel was molded into a head cap and introduced between the head and surface coil, which was followed by shimming and acquisition of field maps. The shape of the head cap was a half moon. It was made by pouring liquid agarose into a plastic tube of 2 cm diameter that had been sliced in half lengthwise. A second tube (1.6 cm diameter) was then placed on top of the hardening gel. In general, the thickness of the caps ranged at the most caudal part being 0.5-1 mm thick and the most rostral part being 1-1.5 mm thick. The cap was 1.5 cm long and as wide as the surface coil.
fMRI Following optimization, 10 animals were employed to assess protocol suitability for repetitive fMRI sessions. All 10 mice were scanned twice (with 3 weeks interval between sessions) and 5 of them received a third session after another 3 weeks rest. Anesthesia preparation was performed as described above with the evaluated medetomidine dose: an initial 0.3 mg/kg bolus followed by a 0.6 mg/ kg/h subcutaneous infusion. Following positioning, local shim was performed using a (4 mm) 3 cube positioned in the brain, including the S1. Field maps were then acquired and used to perform MAP-Shim with the same cube volume. GE-EPI was performed as described above (cf. Image quality experiments) with 5 consecutive (1 mm thin) coronal slices with the central slice positioned in the center of the S1 (3.5 mm caudal to the rhinal fissure). Forepaw stimulation was performed with the above described parameters (cf. SSEP recording) in a paradigm that employed 140 repetitions, consisting of 5 blocks. Each block consisted of a 45 s resting period and a 30 s activation period. The fMRI scan ended with an additional 45 s resting period, which resulted in a total scan time of 7 min. Animals were allowed to rest for 5 min between fMRI scans. The number of fMRI scans per paw varied between 4 (long sedation) and 2 (short sedation) and was randomized between left and right paw. An additional GE-EPI scan with 60 repetitions but no stimulation was included in order to determine temporal signal-to-noise ratio (tSNR).
Image analysis
Temporal signal-to-noise ratio (tSNR) was calculated voxelwise using ImageJ software (Rasband, 1997 (Rasband, -2009 , by dividing the mean signal intensity of the 60 individual images by its standard deviation over time. Subsequently, circular regions of interest (ROIs) of 25 pixels from each, the left and right forepaw representation in the somatosensory cortex, were averaged to obtain one representative tSNR value for each animal per session.
T2* values were acquired from 5 coronal slices (1 mm slice thickness, 128 × 128 pixel matrix, 1.28 cm × 1.28 cm field of view, 30°fl ip angle) during resting phases in between fMRI scans, using a multigradient-echo sequence (MGE) with 10 echoes ranging from 5 to 50 ms and a TR of 2500 ms. T2* maps were calculated using ImageJ software and average T2* values were obtained from two regions of interest (circles of 104 pixels) from the left and right primary somatosensory cortex of the central slice through the S1.
Statistical analysis was performed with STIMULATE software (Strupp, 1996) using a pixel by pixel paired Student´s t-test and a 95% confidence level. The largest cluster of activated pixels of the central image slice was taken for further analysis. The number of activated pixels was counted and the percentage signal change of each pixel was averaged into a mean percent BOLD change for the cluster.
Results
Repetitive medetomidine sedation was well tolerated by mice. Most animals recovered to a normal activity level within 2 min after atipamezole administration. One animal was lost during the second fMRI experiment due to experimental error. Following the third administration of medetomidine, 2 of the 5 mice died within 4 h after what appeared to have been a normal recovery.
Dose response
Maximal sedation length during the dose response study performed on 12 mice on the bench was around 90 min (Fig. 1A) . Mice which received an initial bolus of 0.3 mg/kg in combination with an continuous infusion of 0.6 mg/kg/h remained sedated for 67 and 62 min while sedation was 93 and 82 min with an initial bolus of 0.4 mg/kg combined with an infusion of 0.8 mg/kg/h. Animals sedated with doses ranging from 0.5 to 0.7 mg/kg (infusion 1.0 to 1.4 mg/kg/h, respectively) exhibited variable sedation lengths, and particularly with the highest dose, recovered slower and exhibited adverse behavior such as hunching and lethargy during 24 h post sedation. Therefore, three animals were euthanized and doses equal to or higher than 0.5 mg/kg were subsequently excluded. Although a bolus dose of 0.4 mg/kg combined with a subsequent infusion of 0.8 mg/kg/h resulted in longest sedation periods, we decided to use a dose of 0.3 mg/kg in combination with a continuous infusion of 0.6 mg/kg/h for functional MRI studies. This decision was based primarily on the fact that the sedation length was more similar in the animals that received the lower of the 2 doses, as well as for safety considerations since already the dose of 0.5 mg/kg with an infusion of 1.0 mg/kg led to unwanted side effects.
In 4 of the 6 animals treated with 0.2-0.4 mg/kg (0.4-0.8 mg/kg/ h infusion respectively), a slight decrease in respiration rate (around 20 breaths/min) was observed between 1 and 5 min after the medetomidine bolus (Fig. 1C) . When isoflurane was discontinued, all animals showed an increase in respiratory rate, which stabilized approximately 20 min after the initial medetomidine bolus. The respiration rate for mice sedated with medetomidine was between 160 and 200 breaths/min. In all animals, transcutaneous pCO 2 showed an initial increase upon medetomidine administration which stabilized after 15 min (Fig. 1D) .
SSEP recording
Investigation of electrophysiological behavior under medetomidine was carried out on 5 animals sedated with 0.3 mg/kg. SSEPs were consistently recorded in the contralateral hemisphere following all 4 stimulations of each forepaw. Average SSEP waveforms for each of the 5 mice are depicted in Fig. 1B . The SSEPs exhibited the standard peaks P1, N1 and P2 with average amplitudes of 148.8 ± 110.6, −135.8 ± 124.3, and 5.1 ± 25.4 µV, and average latencies of 20.4 ± 1.0, 28.9 ± 1.3, and 37.1 ± 4.8 ms, respectively, as summarized in Table 1 .
Image quality experiments
The small mouse brain makes shimming difficult, and image distortions were prevalent. This was particularly so in regions of tissue interface changes, such as the cortex, and therefore, there was often loss of signal in the S1. Several strategies were employed to investigate this situation. Field maps of the brain were acquired for different positions of the S1 relative to the isocenter of the magnet along the z-axis (Fig. 2A) . Magnetic field inhomogeneities were located in the olfactory bulbs and posterior half of the brain. This was found to be independent of animal position relative to the isocenter. Therefore, different shim strategies were employed, including Global Shim, Local Shim and MAPSHIM, but none succeeded alone or in combination in recovering the lost signal in the S1 (Fig. 2B-C) . However, the introduction of an agar head cap between the head and surface coil (Fig. 2F) , substantially improving the susceptibility homogeneity across the mouse head volume, significantly improved the image quality (Fig. 2D-E) , even before shimming. Homogeneity drastically improved at the level of the eyes, as well in the posterior half of the brain (Fig. 2E) . However, following shimming on the (4 mm) 3 shim volume, geometric distortions appeared in the lower brain parts with varying intensity.
fMRI
The 10 mice that underwent fMRI experiments exhibited slightly longer sedation periods (112 ± 21 min, n = 24 anesthesia sessions) with 0.3 mg/kg medetomidine than was earlier observed during the dose response experiments. Sedation length varied between the animals, and therefore also the number of performed scans per session varied between 4 and 8 (Table 2) . Following the stimulation of each forepaw, BOLD activation was detected in the contralateral S1 in approximately 50% of the performed scans (Table 2) . Despite this somewhat variable situation from scan to scan, we reproduced the BOLD response between two independent sessions in 6 animals ( Fig. 3C-H) .
Results for all 10 mice over both fMRI sessions are summarized in Table 2 . Overall, during the first fMRI session, a significant BOLD response was detected in 8 of the 10 mice ( Table 2) . One of these eight animals died during the second session, and of the remaining seven mice, six showed a BOLD response during the second session (Fig. 3C-H) . The remaining two animals that did not show BOLD response during the first session did, however, exhibit a strong response during the second session (Table 2) . Despite the overall trend, there was some variability of BOLD detection between individual scans in some animals. BOLD was detected in every scan in 2 animals during the first session (Table 2 : Animals 4 + 8). However, in some animals, especially during the second session, only one BOLD positive scan was observed per session (Table 2 : Animals 2, 6, 7, 9, and 10). BOLD prevalence from the first session across all animals was 30 BOLD positive scans out of 52 performed scans (57.7%). Following the second session, prevalence decreased to 45 positive scans out of 105 performed scans (42.9%). The average increase in the BOLD signal fluctuated around 1% with the Table 1 Average SSEP peak latency and amplitude recorded during forepaw stimulation over the S1 from medetomidine anesthetized mice. overall average over both sessions of 1.3± 0.4%. The average number of BOLD positive pixels in the center slice varied from 5 to 13, with an overall average of 7.4± 4.4 pixels ( Table 2) . As can be seen in Fig. 3B + I-K, spontaneous fluctuations of the signal challenge the easy monitoring of the fMRI signal. Especially, BOLD signal peaks were not sustained over the period of stimulation. Nevertheless, average signal increase during stimulation periods was significant at a confidence level of 95%. Temporal SNR was subject to some variation between sessions. All 10 mice showed a good and stable temporal SNR of 48 ± 6 during the first session, which decreased, however, during the second session to 39 ± 11. Specifically, the first 4 animals of the second session had a good tSNR of 50 ± 6, while the 5 last scanned mice had a tSNR of 27 ± 4. However, the detectability of the BOLD response did not appear to be dependent on tSNR, since no correlation was found between the total number of activated pixels weighted by the number of performed scans of one session and the tSNR value (R 2 = 0.07). Nevertheless, the 5 mice with the lowest tSNR (around 27) during the second session underwent a third fMRI session. tSNR was significantly improved to 41± 7 during the third session. The average BOLD response was comparable to the previous sessions (1.4 ± 0.3% signal increase) with an average of 10.8 ± 6.5 activated pixels. Total BOLD outcome of all three sessions was 53 BOLD positive scans from 131 performed scans (40.5%). T2* values for the left and right somatosensory cortex varied between 10 and 23 ms. The overall average of the T2* value was 18.0 ± 3.5 ms.
Discussion
In the present study, we have established a longitudinal and noninvasive protocol for fMRI of the somatosensory cortex of mice. Medetomidine, an α 2 -adrenoreceptor agonist, was used to achieve sedation. Following evaluation of the optimal dose of 0.3 mg/kg, the sedation was characterized by a stable respiration rate and transcutaneous CO 2 level. Somatosensory evoked potentials (SSEPs) were recorded during electrical forepaw stimulation from the contralateral S1 in medetomidine sedated mice and subsequent BOLD change was observed longitudinally in 6 of 9 mice, which underwent longitudinal fMRI. The BOLD response was specific to the stimulus, showing the largest cluster of activated pixels in the S1 cortex contralateral to the stimulated forepaw. This protocol will allow for the first time access to the investigation of functional brain activation changes in different transgenic mouse models. Furthermore, it will help to elucidate mechanisms of functional brain deficit and recovery, respectively, in mice having undergone brain injury such as e.g. stroke and stem cell therapy.
Somatosensory evoked potentials showed the well established shape of a fast positive deflection (P1) followed by a fast negative deflection (N1) and a second positive wave (P2), which is consistent with literature for rodent SSEPs (Brinker et al., 1999; Franceschini et al., 2008; Gsell et al., 2006) . The amplitude of P1 and N1 is in good agreement with previously recorded SSEPs from the S1 cortex in mice, P1 = 51.3 ± 6.4 µV, N1= −93.6 ± 11 µV (Troncoso et al., 2000) . In the present study, the average amplitudes varied in the range of 56 to 336 µV for P1 and from −34 to −332 µV for N1 between individual animals. Also the ratio of P1 to N1 amplitude is subject of variation, and mostly P1 is larger than N1. This is different than previously observed in α-chloralose anesthetized rats. We cannot exclude that a sedation effect may contribute to the amplitude differences and ratio variations among animals, but it can also be influenced by small differences in electrode position, as well as contact quality. Furthermore, Troncoso et al. proposed light anesthesia as a confounding factor in SSEP recordings, resulting in decreased SNR due to cortical desynchronization (Troncoso et al., 2000) , which may also have contributed to the observed variation in the ratio of P1 to N1 amplitude. However, it is noteworthy that Hayton et al. (1999) , in earlier studies of SSEPs of rats under medetomidine, reported P1/N1 amplitude ratios very much in line with our present results. These authors argued that medetomidine as an α2 adrenergic receptor agonist disrupts the signal transduction from thalamus to cortex and therefore more synapses have to be passed in order to generate cortical components. Latencies for P1 and N1 were extremely stable (20.6 ± 1.1 ms and 29.8 ± 1.9 ms, respectively), although they are somewhat longer than what has been observed previously: (14 ±0.6 ms and 24± 1.1 ms) (Troncoso et al., 2000) . One possible explanation for this is that Troncoso et al. used pentobarbital to produce anesthesia, and different anesthetic agents have been shown to produce different effects on both the latencies and amplitudes of SSEPs (Hayton et al., 1999) . Furthermore, it has been shown that the optimal frequency of the forepaw stimulation can be different depending on the anesthetic agent. For example, a frequency of 1.5-3 Hz resulted in the largest amplitude SSEP recordings in α-chloralose anesthetized rats (Brinker et al., 1999; Silva et al., 1999) , whereas this was reported to be 8-12 Hz for isoflurane anesthetized rats (Masamoto et al., 2007) . We used a frequency of 6 Hz because the BOLD response under medetomidine sedation was shown to be maximal in the range between 6 and 9 Hz in rats (Zhao et al., 2008) . While no other frequencies were tested in our hands, the results show that stable SSEPs can be obtained with the selected 0.3 mg/kg medetomidine dose.
A BOLD response was observed (53/131 scans) using our sedation strategy with a mean signal change around 1.3 ± 0.4%. This is comparable to other studies that employed isoflurane and similar stimulation parameters (2 mA, 0.3 ms pulse width, but 3 Hz instead of 6 Hz) at 9.4 T (Nair and Duong, 2004) . A higher BOLD response was produced to around 3% by increasing the stimulation current to 6 mA while decreasing the isoflurane concentration to 0.75% (Nair and Duong, 2004) . However, irregular respiration patterns and changes in mean arterial blood pressure (MABP) were reported when stimulation was increased to 7 mA, suggesting a non-specific BOLD effect already at 6 mA due to a contribution of pain response. Also in isoflurane anesthetized rats, a current of minimum 6 mA was reported necessary to result in a BOLD increase of approximately 1% (Liu et al., 2004) . However, despite these apparent positive BOLD reports of isoflurane as a gaseous anesthetic with the advantage of good control over anesthesia depth and fast recovery, it is known to be a suppressor of neuronal activity and a potent vasodilator. Isoflurane decreased the amplitudes of evoked potentials by 54% and increased cerebral blood flow by 45% when compared to α-chloralose (Masamoto et al., 2007) . Since the BOLD response is highly dependent on CBF (Cohen et al., 2002) , most fMRI studies tend to avoid isoflurane in favour of α-chloralose in order to preserve functional-metabolic coupling (Ueki et al., 1992) . However, the α 2 -adrenergic receptor agonist medetomidine, employed in the present study, is now increasingly preferred due to the ease of implementation and, more importantly still, because Mean BOLD change ± standard deviation 1 3/6 8.0 ± 2.6 1.5 ± 0.4 5/7 6.4 ± 2.6 1.2 ± 0.3 2 2/6 5.0 ± 3.8 1.4 ± 0.4 1/4 6 0.8 3 2/3 11.5 ± 2.1 1.2 ± 0.5 2/4 11.5 ± 9.2 0.9 ± 0.1 4 6/6 13.3 ± 6.4 1.4 ± 0.2 -* -* -* 5 3/6 9.7 ± 4.9 1.5 ± 0.4 3/8 5.3 ± 1.5 1.0 ± 0.1 6 6/6 7.8 ± 3.5 0.9 ± 0. of its option to perform longitudinal experiments in the same animals (Pawela et al., 2008; Weber et al., 2008 Weber et al., , 2006 Zhao et al., 2008) . Similar to α-chloralose (Lindauer et al., 1993; Nakao et al., 2001) dexmedetomidine, the active ingredient of medetomidine is known to reduce cerebral blood flow, as measured by laser Doppler flowmetry in rats (Ganjoo et al., 1998) . BOLD increase in medetomidine sedated rats does not appear to differ from α-chloralose anesthetized rats, and was in the same percentage range (1-1.5%) (Pawela et al., 2008; Weber et al., 2006; Zhao et al., 2008) as observed in our study. However, there are important differences in medetomidine sedation between rats and mice. Maximal average sedation duration in mice achieved in this study was almost 2 h while up to 3.5 h were obtained in rats (Weber et al., 2006) . This has been reported to be even extendable up to 6 h (Pawela et al., 2009) . However, increasing the dose above 0.4 mg/kg did not increase sedation duration but, instead, resulted in a potential overdose so that some mice had to be euthanized. Since medetomidine also activates α 1 -adrenergic receptors, it is possible that arousal and vigilance were increased with higher doses. Studies reviewed by Sinclair et al. (Sinclair, 2003) have shown that activation of central α 1 -adrenergic receptors antagonizes the sedative response to even potent α 2 -agonists, such as medetomidine, particularly with high (toxic) doses. The dose of 0.3 mg/kg with a continuous infusion of 0.6 mg/kg/h used here provided stable respiration and transcutaneous recording of CO 2 at a sufficient sedation to perform the fMRI experiments. We cannot exclude that further experimenting with the protocol may further improve the sedation length, though the reported duration was more than sufficient for our purposes. Also repetitive sedation with the dose of 0.3 mg/kg in combination with an infusion of 0.6 mg/kg/h was well tolerated by most mice. However, two mice died in a time window of 4 h after the second sedation, which we cannot exclude to be in context with the sedation.
Using the same field strength as in the present study (11.7T), Ahrens et al. (Ahrens and Dubowitz, 2001 ) observed a 7% BOLD change in mice, sedated with α-chloralose, upon electrical hindpaw stimulation with much lower stimulation of 50 µA and 3 Hz, the optimal stimulation frequency for α-chloralose anesthesia in rats (Gyngell et al., 1996; Keilholz et al., 2004; Silva et al., 1999) . The BOLD intensity in that report is clearly higher than our observed 1.4 + 0.3%. Differences in spatial resolution (leading to varying partial volume dilution of the BOLD effect) can be excluded as explanation: we used 200 × 200 × 1000 µm 3 while Ahrens and Dubowitz reported 180 × 180 × 1500 µm 3 . We believe that the difference in BOLD strength must rather be sought for in the physiological and experimental conditions. While all studies so far dealing with electrical paw stimulation needed 1-2 mA for a detectable stimulation, Ahrens and Dubowitz used only 50 µA. As we know from our earlier fMRI studies in rats, hindpaws (used by Ahrens and Dubowitz) need even higher currents than forepaws (Bock et al., 1998) . That makes detectability of activation in the somatosensory cortex difficult to understand when using only 50 µA. It appears most likely that the authors recorded at such low stimulation current only slight hemodynamic responses in larger vessels at the surface of the cortex instead of in the deeper layers of the S1 cortex area itself. In favor of this explanation speaks the rather short TE of 7 ms chosen by Ahrens and Dubowitz for their FLASH fMRI experiments compared to the 17.5 ms used in the present study. As shown by Grüne et al. (1999) in FLASH-based fMRI experiments on the somatosensory cortex in rats, the susceptibility gradient from tissue to bone leads to increasing weighting of the BOLD signal to cortical surface vessels with decreasing TE values. Functional brain activation in mice has also been measured with cerebral blood volume (CBV) using an intravenous contrast agent and rapid acquisition relaxation enhancement (RARE) sequence (Mueggler et al., 2001) . Changes in CBV upon hindpaw stimulation with 1.5 Hz and 2 mA were around 17%, but temporal resolution was lacking with 21 s per image. Furthermore, this CBV-based fMRI approach has the disadvantage of invasive addition of contrast agent and, in consequence, limited repetitions of activation scans following the contrast agent injection.
The reproducibility of the BOLD response was approximately 50% in the present study. The BOLD response in rats sedated with the medetomidine protocol is more stable, but is also subject to variations. One reason for the lower robustness of the protocol in mice is obviously the strong spontaneous fluctuation of the signal visible in the time courses. Clearly the noise is a complicating factor of mouse fMRI, leading to noisier signal-time curves than in rats. Although transcutaneous CO 2 was stable during the period of sedation, we did not measure absolute partial pressure of CO 2 in arterial blood. We therefore cannot exclude the possibility of a suppressing effect of high CO 2 levels on the hemodynamic response and consequently on BOLD.
Image quality is a key factor for reproducible fMRI experiments. Susceptibility artifacts are prevalent at interfaces of air, bone and tissue and can cause strong local field gradients, leading in consequence to signal loss in T2*-weighted images . This is particularly so at high magnetic field and is further compounded by the difficulty in shim optimization over small sample volumes like the mouse brain (Ahrens and Dubowitz, 2001; Nair and Duong, 2004) . In the present study, T2* values were variable in the S1 cortex from session to session (10-24 ms), consistent with previous reports that suffered even greater variations which those authors did not succeed in removing by shimming (Ahrens and Dubowitz, 2001 ). We experienced similar field gradients, and the 2nd order MAPSHIM failed repeatedly. However, the introduction of agar in between the mouse head and surface coil substantially increased the field homogeneity so that 2nd order MAPSHIM could be applied successfully. Temporal stability of our image series was found variable between separate sessions (tSNR = 20-60). The variability of the tSNR in our GE-EPI images can be the result of many influencing factors, including physiological factors like respiration rate and heart rate. But most likely we believe that the newly introduced agar head cap leads to a somewhat variable distance between rf surface coil and brain. This will in the future be further optimized.
Conclusions
With the present study, we have established a new, experimental protocol for fMRI studies in mice under controlled physiological conditions. We have demonstrated the feasibility to perform longitudinal and non-invasive fMRI studies following forepaw stimulation in mice sedated with medetomidine. A reproducible BOLD signal was observed in the somatosensory cortex, demonstrating that this new protocol is well suited to be applied for functional brain activation studies in transgenic animal models or for investigations on functional deficit and recovery, respectively, for the assessment of therapeutical strategies in models of brain injury.
